Chronic Bronchitis: Symptoms, Causes & Treatment
التهاب القصبات المزمن
Chronic bronchitis is a chronic airway inflammation defined by a productive cough lasting at least three months per year for two consecutive years, most often caused by long-term smoking.
What is Chronic Bronchitis?
Chronic bronchitis is the mucus hypersecretory phenotype of chronic obstructive pulmonary disease (COPD), defined clinically as a productive cough on most days for at least 3 months in each of 2 consecutive years, after excluding other causes such as bronchiectasis, tuberculosis, or asthma. It affects approximately 5% of adults worldwide, rising to 40–50% among long-term heavy smokers. Approximately 50% of patients with chronic bronchitis will develop airflow limitation meeting COPD criteria.
Tobacco smoke and other inhaled irritants trigger sustained airway inflammation that leads to hypertrophy and hyperplasia of mucous glands (Reid index — gland-to-wall ratio >0.4), increased goblet cell density, and impaired mucociliary clearance. The resulting excess viscous mucus impedes airflow and creates a favorable environment for bacterial colonization — predominantly Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis — leading to recurrent acute exacerbations of chronic bronchitis (AECB) that accelerate lung function decline.
Spirometry is essential: post-bronchodilator FEV1/FVC <0.70 confirms fixed airflow obstruction. Smoking cessation is the only intervention proven to slow the FEV1 decline rate; all other treatments (bronchodilators, ICS, roflumilast, mucolytics) manage symptoms and reduce exacerbation frequency without reversing the underlying pathology.
Symptoms
- Chronic daily productive cough, worst in the morning (sputum initially clear/grey, becomes yellow-green during infections)
- Progressive exertional dyspnea — COPD component
- Wheeze and chest tightness from airflow obstruction
- Recurrent acute exacerbations: increased sputum volume/purulence, worsened dyspnea
- Finger clubbing and cyanosis in severe advanced disease
Causes
- Long-term cigarette smoking — primary cause in over 90% of cases; risk correlates with pack-year history
- Chronic occupational exposure: coal dust, grain dust, silica, chemical fumes
- Indoor air pollution from biomass fuel combustion (major cause in low-income countries)
- Recurrent childhood respiratory infections impairing lung development
- Alpha-1 antitrypsin deficiency — genetic predisposition to early-onset COPD/bronchitis
Diagnosis
Clinical diagnosis based on the standard definition: productive cough ≥3 months/year for ≥2 consecutive years. Spirometry is mandatory: post-bronchodilator FEV1/FVC <0.70 confirms COPD component; FEV1 % predicted grades severity. Chest X-ray: hyperinflation, increased bronchovascular markings — helps exclude pneumonia, heart failure, malignancy. Sputum culture during exacerbations guides antibiotic selection. Alpha-1 antitrypsin levels in young patients or those with minimal smoking history.
Treatment
Smoking cessation: the single most important intervention — slows FEV1 decline and reduces exacerbation frequency. Pharmacotherapy: short-acting bronchodilators (SABA/SAMA) for rescue; long-acting bronchodilators (LABA + LAMA combination) as maintenance; inhaled corticosteroids (ICS) combined with LABA reduce exacerbation frequency in patients with ≥2 exacerbations/year. Roflumilast (PDE-4 inhibitor) for severe chronic bronchitis with frequent exacerbations. Antibiotics (amoxicillin-clavulanate, azithromycin, or doxycycline) for acute exacerbations. Pulmonary rehabilitation. Influenza and pneumococcal vaccination. Long-term oxygen therapy for resting hypoxemia (PaO2 <55 mmHg).
Complications
- Progression to fixed-obstruction COPD with irreversible airflow limitation
- Recurrent acute exacerbations (AECB) accelerating annual FEV1 decline
- Pulmonary hypertension and right heart failure (cor pulmonale) from chronic hypoxemia
- Respiratory failure requiring long-term oxygen therapy or mechanical ventilation
- Increased risk of lung cancer (shared risk factor: smoking)
Prevention
- Never smoking is the most effective prevention strategy
- Smoking cessation at any age slows disease progression and reduces exacerbation risk
- Occupational respiratory protection: masks, ventilation, dust control in at-risk workplaces
- Annual influenza vaccine and pneumococcal vaccine reduce exacerbation frequency and hospitalizations
When to see a doctor
See your doctor for any cough lasting more than 3 weeks, increased or discolored sputum, exertional breathlessness, or acute worsening with fever suggesting an exacerbation. Early spirometry to detect COPD before severe lung damage occurs — and smoking cessation counseling at every visit — are the most impactful interventions for long-term prognosis.